**STUDY COHORT**
120 resected PDACs with clinicopathological information and up to 196 months follow-up

Immunohistochemical staining (n=120) for MLH1, MSH2, MSH6 and PMS2 and exclusion of 2 MSI-cases

Immunohistochemical staining (n=118) for PD-1/PD-L1 and identification of 38 PD-L1+cases (32%)

**VALIDATION COHORT**
229 resected PDACs with clinicopathological information and up to 190 months follow-up

Immunohistochemical staining (n=229) for MLH1, MSH2, MSH6 and PMS2 and exclusion of 3 MSI-cases

Immunohistochemical staining (n=226) for PD-1/PD-L1 and identification of 67 PD-L1+cases (30%)

**Next Generation Sequencing** (n=112) (Oncomine Comprehensive Assay v3 panel)

**Morphometric and proximity analysis of all PD-L1+cases of the study cohort (n=38) by multiplex immunofluorescence for CD3, CD4, CD8, FOXP3, CD68, CD206, PD-1, PD-L1 and Pancytokeratin**

**Suppl Figure 1**
Suppl Figure 2
Distribution of the CD3+CD8+ Phenotypes across the Different Patterns of PD-L1-mediated Immune Resistance

**Intraepithelial Compartment**

- **Adaptive 1**
  - CD3+CD8+ 82%
  - CD8+PD-L1+ 2%
  - CD8+PD-1+ 16%

- **Adaptive 2**
  - CD3+CD8+ 87%
  - CD8+PD-L1+ 8%
  - CD8+PD-1+ 5%

- **Combined**
  - CD3+CD8+ 53%
  - CD8+PD-L1+ 46%
  - CD8+PD-1+ 1%

**Stromal Compartment**

- **Adaptive 1**
  - CD3+CD8+ 85%
  - CD8+PD-L1+ 12%
  - CD8+PD-1+ 3%

- **Adaptive 2**
  - CD3+CD8+ 49%
  - CD8+PD-L1+ 51%
  - CD8+PD-1+ 0%

- **Combined**
  - CD3+CD8+ 71%
  - CD8+PD-L1+ 27%
  - CD8+PD-1+ 2%

Suppl Figure 3
Suppl Figure 4
Suppl Figure 5
Suppl Figure 6
Suppl Figure 8